Vifor Pharma Group Supports Rare Disease Day 2019
The Vifor Pharma Group today announces its support of Rare Disease Day, joining patients and healthcare providers around the world to support a day that raises awareness of the impact that rare diseases have and highlights the need for a greater understanding of these debilitating conditions.
Rare Disease Day is coordinated on an international scale by the European Organisation for Rare Diseases (EURORDIS) and the National Organisation for Rare Disorders (NORD) in the US. The Rare Disease Day 2019 slogan is ‘Show Your Rare, Show You Care’ and is focused on ‘Bridging health and social care’ to address the challenges people affected by these diseases face every day. According to EURORDIS there are over 6,000 known rare diseases affecting over 300 million people worldwide.
Vifor Pharma is committed to improving the lives of patients with rare diseases around the world where high unmet medical needs exist. The company is currently developing new treatment options for three debilitating conditions:
- ANCA-associated vasculitis: ANCA-associated vasculitis is a rare, severe small vessel vasculitis affecting multiple organs with a long-term relapsing, remitting course. In partnership with ChemoCentryx, Inc., Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has a product in phase-III clinical trial which expects to read out in the fourth quarter of 2019.
- Focal segmental glomerulosclerosis (FSGS): FSGS is an orphan disease of the kidney’s filtering units (glomeruli) and is characterised by serious scarring that leads to permanent kidney damage. There are currently no approved treatment options for FSGS patients. In partnership with ChemoCentryx, VFMCRP is currently developing a compound for FSGS which is currently in phase-II clinical trial.
- Beta-thalassemia: Beta-thalassemia is an inherited, rare blood disorder that reduces the production of functional haemoglobin in red blood cells, which can lead to a lack of oxygen in many parts of the body potentially causing anaemia. Severe forms can cause serious, even life-threatening complications if left untreated. Beta-thalassemia is often treated with blood transfusions which may lead to excess levels of iron in the body (iron overload). Vifor Pharma recently reported positive phase-I trial results for its oral ferroportin inhibitor and it intends to start a phase-II in the second half of 2019.
In support of Rare Disease Day, VFMCRP was a proud sponsor of the EURORDIS Black Pearl Awards – an annual event held in Brussels to recognise the outstanding achievements and exceptional work of people making a difference for the rare disease community.
“Although there has been significant progress in developing new treatments for rare diseases, there remains clear unmet need in many debilitating conditions, including ANCA-associated vasculitis where patients have to battle a severe illness, and also face difficult treatment decisions with life-long implications for their health,” said Peter Rutherford, Global Medical Lead, Orphan Renal Diseases, Vifor Pharma. “Rare Disease Day is an occasion for us at Vifor Pharma to reaffirm our strong commitment to developing new treatments and raising awareness in the conditions where we are focused.”
About the Vifor Pharma Group
The Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. The Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. The Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; VFMCRP, a joint company with Fresenius Medical Care; Relypsa; and OM Pharma. The Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit www.viforpharma.com.
About Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP)
Vifor Fresenius Medical Care Renal Pharma is a common company of the Vifor Pharma Group and Fresenius Medical Care, which develops and commercialises innovative and high-quality therapies to improve the lives of patients suffering from chronic kidney disease (CKD) worldwide. The company was founded at the end of 2010 and is owned 55% by Vifor Pharma Group and 45% by Fresenius Medical Care. For more information about VFMCRP and its parent companies, please visit www.vfmcrp.com, www.viforpharma.com and www.freseniusmedicalcare.com.
About EURORDIS, Rare Disease Europe
EURORDIS-Rare Diseases Europe is a unique, non-profit alliance of 826 rare disease patient organisations from 70 countries that work together to improve the lives of the 30 million people living with a rare disease in Europe. By connecting patients, families and patient groups, as well as by bringing together all stakeholders and mobilising the rare disease community, EURORDIS strengthens the patient voice and shapes research, policies and patient services. www.eurordis.org
Anti-neutrophil cytoplasmic anti-body (ANCA)-associated vasculitis
ANCA-associated vasculitis is a group of rare, relapsing/remitting, life-threatening, autoimmune diseases. ANCA-associated vasculitis can affect small blood vessels in different parts of the body resulting in damage to vital organs such as the lungs, kidneys, nervous system, gastrointestinal system, skin, eye and heart. ANCA-associated vasculitis is caused by the loss of tolerance to ANCA antigens and the development of an autoantibody, ANCA. This is a complex process involving genetic and environmental factors.3–8
Beta-thalassemia is a heterogeneous autosomal recessive hereditary anaemia characterised by reduced or absent β globin chain synthesis. The resulting relative excess of unbound α globin chains precipitate in erythroid precursors in the bone marrow, leading to their premature death and, hence, to ineffective erythropoiesis. β-thalassemia phenotypes are variable, ranging from the severe transfusion dependent thalassemia major to the mild form of thalassemia intermedia.9 When transfusion therapy is considered, careful attention to the potential risks of iron overload should be made.10
Focal segmental glomerulosclerosis (FSGS)
Focal segmental glomerulosclerosis (FSGS) is an orphan and frequently idiopathic disease that can cause scarring in specific parts of the kidney or the filters of the organ.11 FSGS is one of the causes of a serious condition known as Nephrotic Syndrome and often leads to end-stage renal disease (ESRD). There is no approved treatment option for FSGS patients.12
1. Rare Disease Day. What is Rare Disease Day? 2019. Available at: https://www.rarediseaseday.org/article/what-is-rare-disease-day. Accessed: February 2019.
2. EURORDIS Black Pearl Awards. Available at: https://blackpearl.eurordis.org/. Accessed: February 2019
3. Watts RA, et al. Nephrol Dial Transplant 2015;30(Suppl 1):i14–22.
4. Geetha D et al. J Nephrol 2015;28:17–27.
5. Hutton H et al. Semin Nephrol 2017;37:418–35.
6. Watts RA, et al. Rheumatology (Oxford) 2017;56:1439–40.
7. Robson J et al. Rheumatol Int 2018;38:675–82.
8. Jennette J and Nachman P. Clin J Am Soc Nephrol 2017;12:1680–91.
9. Danjou F, et al. Haematologica 2011;96:1573–753.
10. Taher A, et al. Guidelines for the Management of Non Transfusion Dependent Thalassemia (NTDT). 2ND EDITION Thalassemia International Federation. Publication No. 22; ISBN 978- 9963-717-11-8.
11. National Kidney Foundation. Focal Segmental Glomerulosclerosis (FSGS) 2017. Available at: https://www.kidney.org/atoz/content/focal. Accessed: February 2019.
12. Reiser J, et al. Adv Chronic Kidney Dis. 2014;21:417–21.
Head of Corporate Communications
Tel.: +41 58 851 80 87
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Knopp Biosciences Presents Positive Preclinical Data for Lead Neonatal Epilepsy Drug Candidate at 2019 Antiepileptic Drug and Device Trials XV Conference24.5.2019 17:00:00 EEST | Tiedote
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today presented in vitro and in vivo data for the company’s lead molecule for the targeted treatment of KCNQ2-neonatal epileptic encephalopathy (KCNQ2-NEE) at the Antiepileptic Drug and Device Trials XV Conference in Miami, Florida. KCNQ2-NEE, a rare infant genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and profound developmental delay. The preclinical data were presented by Steven Dworetzky, Ph.D., Knopp’s Chief Scientific Officer, a longtime Kv7 researcher who led the group that first cloned the Kv7.2 and Kv7.3 genes during his former tenure with the Bristol-Myers Squibb Co. Dr. Dworetzky presented results demonstrating the in vitro nanomolar activity of KB-3061 and its significant seizure protection in the maximal electroshock mo
Accelerate Your Business in South Korea Through 2019 K-Startup Grand Challenge24.5.2019 13:20:00 EEST | Tiedote
Entrepreneurs from across the globe should set their sights on participating in the 2019 K-Startup Grand Challenge. Supported by the Ministry of SMEs and Startups and National IT Industry Promotion Agency (NIPA) of South Korea, the initiative provides invaluable support and comprehensive resources to early age startups. Applications for the K-Startup Grand Challenge are currently being accepted through June 14, 2019. In order to advance in the program, teams must pass a regional audition. A judging panel of startup ecosystem experts and Korean accelerators will select 40 teams to participate in an enriching 3.5 month-long acceleration program in Korea. The selected teams will have exclusive access to free office space at the Startup Campus in Pangyo Techno Valley, one-on-one mentoring, information sessions, coaching on Korean and Asian business culture and the chance to attend insightful seminars on accounting regulations to tax laws, patents and more. Opportunities for networking with
New Investigational Clinical Data for Ipsen’s Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting24.5.2019 08:00:00 EEST | Tiedote
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from clinical studies on investigational uses of cancer medicines cabozantinib (Cabometyx®), liposomal irinotecan (Onivyde®), and lanreotide autogel (Somatuline®, marketed as Somatuline Depot® in the United States) will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting takes place in Chicago, Illinois, U.S., 31 May–4 June 2019; data featuring Ipsen medicines includes: New data from the Phase 3 CELESTIAL trial on the association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma Overview of the Phase 3 COSMIC-312 trial of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma who have not received previous systemic anticancer therapy First Phase 2 data from the CaboGIST study (trial 1317) from the European Organization for Research and Treatment of
The Posiflex Group Showcases an Ecosystem of Connected Solution Endpoints with IoT Remote Monitoring at Computex 201924.5.2019 04:00:00 EEST | Tiedote
For the Computex 2019 show, The Posiflex Group is featuring leading solution technology from the family of brands as a fully Serviced IoT Ecosystem. Solution end points include: Connected Modular Kiosks, POS Terminals, and Digital Signage solutions from Posiflex and KIOSK Information Systems Smart Medical Displays with gesture controls from Portwell Connected Gaming Solutions with Player Tracking Technology from Portwell subsidiary, Ganlot The booth display is based on common field service endpoints represented in a European Manor Destination Resort setting. Field solutions for an array of vertical market applications include QSR ordering, cinema ticketing, fashion retail customer loyalty, interactive signage, hotel / medical center check-in and bill pay, as well as casino gaming technology. This year, in addition to their renowned POS product suite, Posiflex will be featuring newly introduced Modular Kiosk platforms (co-designed by KIOSK and Posiflex), which are configure-to-order sta
Audi China President Thomas Owsianski to Keynote at CES Asia 201923.5.2019 23:00:00 EEST | Tiedote
The Consumer Technology Association (CTA)TM today announced that Thomas Owsianski, president of Audi China, will deliver a keynote address at the upcoming CES Asia 2019. Now in its fifth year, CES Asia will run June 11-13, 2019 at the Shanghai New International Expo Centre (SNIEC) in Shanghai, China. Thomas Owsianski’s keynote is scheduled for 4 PM, Tuesday, June 11, where he will unveil Audi’s vision in transforming mobility from a driving experience to a digital adventure. Mr. Owsianski joined the top management team of Audi China in August 2018 and was named President in October 2018. “Audi has been at the forefront of driving global transformation in the automotive industry through their breakthrough advancements in technology,” said Karen Chupka, executive vice president, CES. “Innovation has revolutionized the transportation experience, and we welcome Mr. Owsianski to the CES Asia stage to share Audi’s vision for the future of global mobility.” Throughout Asia and beyond, technol
ITechLaw Publishes New Book and Opens Global Public Comment Period on Draft Principles for Responsible Artificial Intelligence23.5.2019 22:11:00 EEST | Tiedote
The International Technology Law Association (ITechLaw) has published Responsible AI: A Global Policy Framework, a new book that provides an in-depth review and eight discussion principles that address some of the hottest technology and moral issues of responsible development, deployment and use of artificial intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190523005752/en/ ITechLaw releases new book, Responsible AI: A Global Policy Framework, and opens public comment period. (Photo: Business Wire) Written by a multi-disciplinary group of 54 technology law experts, industry representatives and researchers from 16 countries, the book offers an actionable framework built on the following principles: Ethical Purpose and Societal Benefit, Accountability, Transparency and Explainability, Fairness and Non-discrimination, Safety and Reliability, Open Data and Fair Competition, Privacy, and AI and Intellectual Property.
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme